OBJECTIVE: Subcutaneous insulin resistance syndrome (SIRS) is a rare entity, characterized by increased resistance to subcutaneous insulin and normal sensitivity to intravenous insulin, with no increase in circulating insulin antibodies. Little is known about its pathophysiology, but it has been suggested to occur due to rapid subcutaneous degradation of insulin. Multiple treatment modalities have been used in the past to treat this condition. METHODS: We illustrate a case of a 17-year-old girl with type 1 diabetes mellitus (T1DM), presenting with recurrent episodes of diabetic ketoacidosis (DKA) due to resistance to subcutaneously delivered insulin. RESULTS: We describe the challenges faced while attempting different modalities during her hospital stay, and eventually using inhaled insulin, which was recently approved by the Food and Drug Administration for use in nonpregnant adults with T1DM. CONCLUSION: SIRS is a difficult condition that may lead to patient frustration and carries a serious risk of recurrent DKA. We described this case to create awareness about SIRS, provide insight into the challenges of its management, and report the use of inhaled insulin to successfully dose meal-time insulin, along with intramuscular glargine for basal insulin.
OBJECTIVE: Subcutaneous insulin resistance syndrome (SIRS) is a rare entity, characterized by increased resistance to subcutaneous insulin and normal sensitivity to intravenous insulin, with no increase in circulating insulin antibodies. Little is known about its pathophysiology, but it has been suggested to occur due to rapid subcutaneous degradation of insulin. Multiple treatment modalities have been used in the past to treat this condition. METHODS: We illustrate a case of a 17-year-old girl with type 1 diabetes mellitus (T1DM), presenting with recurrent episodes of diabetic ketoacidosis (DKA) due to resistance to subcutaneously delivered insulin. RESULTS: We describe the challenges faced while attempting different modalities during her hospital stay, and eventually using inhaled insulin, which was recently approved by the Food and Drug Administration for use in nonpregnant adults with T1DM. CONCLUSION: SIRS is a difficult condition that may lead to patient frustration and carries a serious risk of recurrent DKA. We described this case to create awareness about SIRS, provide insight into the challenges of its management, and report the use of inhaled insulin to successfully dose meal-time insulin, along with intramuscular glargine for basal insulin.
Authors: A A E M van Alfen-van der Velden; C Noordam; B E de Galan; J J G Hoorweg-Nijman; P G Voorhoeve; C Westerlaken Journal: Pediatr Diabetes Date: 2009-09-16 Impact factor: 4.866
Authors: J A Galloway; C T Spradlin; R L Nelson; S M Wentworth; J A Davidson; J L Swarner Journal: Diabetes Care Date: 1981 May-Jun Impact factor: 19.112
Authors: J P Riveline; M C Vantyghem; C Fermon; C Brunet; J F Gautier; E Renard; G Charpentier Journal: Diabetes Metab Date: 2005-11 Impact factor: 6.041
Authors: Julio Rosenstock; William T Cefalu; Priscilla A Hollander; Sol S Klioze; Joann Reis; William T Duggan Journal: Diabetes Technol Ther Date: 2009-11 Impact factor: 6.118
Authors: G F Maberly; G A Wait; J A Kilpatrick; E G Loten; K R Gain; R D Stewart; C J Eastman Journal: Diabetologia Date: 1982-10 Impact factor: 10.122
Authors: H Buchwald; E P Chute; F J Goldenberg; C R Hitchcock; B J Hoogwerf; J J Barbosa; W M Rupp; T D Rohde Journal: Ann Surg Date: 1985-09 Impact factor: 12.969
Authors: Kacey Chae; Jordan Perlman; Ryan B Fransman; Christopher L Wolfgang; Ana De Jesus-Acosta; Nestoras Mathioudakis Journal: AACE Clin Case Rep Date: 2021-06-11